Oxagen Limited
Records under this name other than patents Oxagen Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,750,027 | Compounds having CRTH2 antagonist activity Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,563,536 | Compounds having CRTH2 antagonist activity Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,536,158 | Compounds having CRTH2 antagonist activity Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,703,956 | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-INDOL-1-YL)-Acetic Acid Formerly held In force · High confidence | In force | High confidence | |
| US 10,011,584 | Polymorphic Form of [5-Fluoro-3-({2-[(4-Fluorobenzene) SULFONYL]PYRIDIN-3-YL}METHYL)-2-Methylindol-1-YL]-ACETIC Acid Formerly held Lapsed on the fee record Ended Jul 3, 2026 · Medium confidence | Lapsed on the fee record | Ended Jul 3, 2026 | Medium confidence |
| US 9,951,042 | Polymorphic Form of [5-Fluoro-3-({2-[(4-Fluorobenzene) Sulfonyl] PYRIDIN-3-YL}METHYL)-2-Methylindol-1-YL]-ACETIC Acid Formerly held Lapsed on the fee record Ended Apr 24, 2026 · High confidence | Lapsed on the fee record | Ended Apr 24, 2026 | High confidence |
| US 7,582,672 | Compounds for the treatment of CRTH2-mediated diseases and conditions Formerly held Term ended Term ended Feb 8, 2026 · From the USPTO record | Term ended | Term ended Feb 8, 2026 | From the USPTO record |
| US 9,828,359 | Process for the preparation of 3-substituted (indol-1-yl)-acetic acid esters Formerly held Lapsed on the fee record Ended Nov 28, 2025 · From the USPTO record | Lapsed on the fee record | Ended Nov 28, 2025 | From the USPTO record |
| US 8,314,257 | Treatment of CRTH2-mediated diseases and conditions Formerly held Lapsed on the fee record Ended Nov 20, 2024 · From the USPTO record | Lapsed on the fee record | Ended Nov 20, 2024 | From the USPTO record |
| US 8,198,314 | Treatment of CRTH2-mediated diseases and conditions Formerly held Lapsed on the fee record Ended Jun 12, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jun 12, 2024 | From the USPTO record |